These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 38188199)

  • 1. Impact of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on the mortality in sepsis: A meta-analysis.
    Yang DC; Xu J; Jian L; Yu Y
    World J Clin Cases; 2023 Dec; 11(36):8498-8506. PubMed ID: 38188199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Premorbid angiotensin converting enzyme inhibitors or angiotensin II receptor blockers in patients with sepsis.
    Hasegawa D; Lee YI; Prasitlumkum N; Chopra L; Nishida K; Smith RL; Sato R
    Am J Emerg Med; 2022 Dec; 62():69-77. PubMed ID: 36270096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3-5: A Network Meta-Analysis of Randomised Clinical Trials.
    Zhang Y; He D; Zhang W; Xing Y; Guo Y; Wang F; Jia J; Yan T; Liu Y; Lin S
    Drugs; 2020 Jun; 80(8):797-811. PubMed ID: 32333236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in peritoneal dialysis patients.
    Zhang L; Zeng X; Fu P; Wu HM
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD009120. PubMed ID: 24953826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preadmission Antihypertensive Drug Use and Sepsis Outcome: Impact of Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin Receptor Blockers (ARBs).
    Hsieh MS; How CK; Hsieh VC; Chen PC
    Shock; 2020 Apr; 53(4):407-415. PubMed ID: 31135703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin II Receptor Blockers but Not Angiotensin-Converting Enzyme Inhibitors Are Associated With a Reduced Risk of Acute Kidney Injury After Major Surgery.
    Yang SY; Huang TM; Lai TS; Chou NK; Tsao CH; Huang YP; Lin SL; Chen YM; Wu VC; Nsarf Study Group
    Front Pharmacol; 2021; 12():662301. PubMed ID: 33967804
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of continuing the use of renin-angiotensin system inhibitors on mortality in patients hospitalized for coronavirus disease 2019: a systematic review, meta-analysis, and meta-regression analysis.
    Liu Q; Fu W; Zhu CJ; Ding ZH; Dong BB; Sun BQ; Chen RC
    BMC Infect Dis; 2023 Jan; 23(1):53. PubMed ID: 36694122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood pressure reduction and clinical outcomes with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: protocol for a systematic review and meta-regression analysis.
    Batty JA; Tang M; Hall M; Ferrari R; Strauss MH; Hall AS
    Syst Rev; 2018 Aug; 7(1):131. PubMed ID: 30144828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EVALUATING THE PRESCRIPTION OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS OR RECEPTOR BLOCKERS IN PATIENTS WITH DIABETES IN JORDAN.
    Mayyas F; Bataineh W; Jarab A
    Endocr Pract; 2017 Nov; 23(11):1289-1296. PubMed ID: 28816537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The divergent protective effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on clinical outcomes of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis.
    Xie Q; Tang S; Li Y
    Ann Palliat Med; 2022 Apr; 11(4):1253-1263. PubMed ID: 34775774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of in-hospital discontinuation with angiotensin receptor blockers or converting enzyme inhibitors on mortality of COVID-19 patients: a retrospective cohort study.
    de Abajo FJ; Rodríguez-Miguel A; Rodríguez-Martín S; Lerma V; García-Lledó A;
    BMC Med; 2021 May; 19(1):118. PubMed ID: 33980231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis.
    Cheng J; Zhang W; Zhang X; Han F; Li X; He X; Li Q; Chen J
    JAMA Intern Med; 2014 May; 174(5):773-85. PubMed ID: 24687000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and the Risk of SARS-CoV-2 Infection or Hospitalization With COVID-19 Disease: A Systematic Review and Meta-Analysis.
    Tleyjeh IM; Bin Abdulhak AA; Tlayjeh H; Al-Mallah MH; Sohail MR; Hassett LC; Siller-Matula JM; Kashour T
    Am J Ther; 2020 Dec; 29(1):e74-e84. PubMed ID: 33395057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers and outcomes in patients with COVID-19: a systematic review and meta-analysis.
    Lo KB; Bhargav R; Salacup G; Pelayo J; Albano J; McCullough PA; Rangaswami J
    Expert Rev Cardiovasc Ther; 2020 Dec; 18(12):919-930. PubMed ID: 32945216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease.
    Sharma P; Blackburn RC; Parke CL; McCullough K; Marks A; Black C
    Cochrane Database Syst Rev; 2011 Oct; (10):CD007751. PubMed ID: 21975774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association Between Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, and Suicide.
    Mamdani M; Gomes T; Greaves S; Manji S; Juurlink DN; Tadrous M; Kennedy SH; Antoniou T
    JAMA Netw Open; 2019 Oct; 2(10):e1913304. PubMed ID: 31617924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.
    Martin N; Manoharan K; Davies C; Lumbers RT
    Cochrane Database Syst Rev; 2021 May; 5(5):CD012721. PubMed ID: 34022072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers in diabetic nephropathy: a systematic review and meta-analysis.
    Du YH; Guan CJ; Li LY; Gan P
    Ann Palliat Med; 2022 Mar; 11(3):1093-1101. PubMed ID: 35365039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum potassium changes due to concomitant ACEI/ARB and spironolactone therapy: A systematic review and meta-analysis.
    Villa-Zapata L; Carhart BS; Horn JR; Hansten PD; Subbian V; Gephart S; Tan M; Romero A; Malone DC
    Am J Health Syst Pharm; 2021 Dec; 78(24):2245-2255. PubMed ID: 34013341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of renin-angiotensin-aldosterone system (RAAS) inhibitors is associated with a lower risk of mortality in hypertensive COVID-19 patients: A systematic review and meta-analysis.
    Wang Y; Chen B; Li Y; Zhang L; Wang Y; Yang S; Xiao X; Qin Q
    J Med Virol; 2021 Mar; 93(3):1370-1377. PubMed ID: 33095513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.